Stay up to date with the latest breakthroughs, scientific publications, and industry developments in the field of CAR-T cell therapy. This category brings together cutting-edge research, expert insights, regulatory updates, and major news from China and around the world. From early-stage discoveries to clinical trial milestones and real-world applications, explore how CAR-T therapy continues to evolve and reshape the landscape of cancer and immune-related disease treatment.
China has become a leading destination for stomach cancer treatment, offering innovative therapies, experienced specialists, and access to new treatment options that may not yet be widely available elsewhere.
A long-term follow-up study from Zhejiang University First Affiliated Hospital found that high Ki-67 expression is associated with poorer responses and shorter progression-free survival after CD19 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin lymphoma. The research also provides important data on the long-term safety and durability of CAR-T treatment.
In 2025, China’s NMPA approved multiple CAR-T cell therapies for hematologic malignancies, including large B-cell lymphoma and pediatric B-ALL. This review highlights the key CAR-T approvals shaping the future of blood cancer treatment in China.
A new fully human CAR-T cell therapy targeting GPRC5D has demonstrated remarkable clinical results in treating relapsed or refractory multiple myeloma (R/R MM), with findings recently published in the top-tier
A groundbreaking study published in Cell shows that BCMA CAR-T therapy Equecabtagene Autoleucel (Eque-cel) achieved promising clinical results in patients with progressive multiple sclerosis, highlighting the potential of CAR-T therapy for autoimmune diseases.
For patients with primary central nervous system lymphoma (PCNSL), the treatment journey often becomes increasingly difficult after relapse. Once conventional therapies fail, many patients are left with few effective options.
This study focuses on a novel CD22-targeted chimeric antigen receptor T-cell therapy (CAR-T CD22-65s) for pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who relapsed after CD19-directed immunotherapy.
Professor Huang He introducing the latest development of CAR T-cell therapy in China at the EBMT-EHA 6th European CAR T-cell Meeting.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.